RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Including Regulatory at the Strategy Table

Including Regulatory at the Strategy Table

Posted 01 December 2010

Transforming a controlled stream of high-quality raw materials into a steady output of products that delight an ever-increasing number of customers is the ultimate goal of any manufacturer. It becomes more critical in highly regulated businesses such as the pharmaceutical and medical device industries. Regulations provide frameworks intended to manage the constant tensions between attaining quality and containing costs. When done correctly, production can maintain a balance between quality and cost such that efficiencies lead to sustainable savings. In turn, those sustainable savings can fuel the development of capabilities to increase volume and diversity of product offerings. Within FDAregulated industries, this cycle of product flow must accommodate a growing number of regulatory requirements that are also increasing in complexity and scope. This is creating the downward spiral that is hindering many companies.


© 2022 Regulatory Affairs Professionals Society.